scispace - formally typeset
Y

Yoshimichi Okayama

Researcher at Nihon University

Publications -  140
Citations -  7022

Yoshimichi Okayama is an academic researcher from Nihon University. The author has contributed to research in topics: Mast cell & Immunoglobulin E. The author has an hindex of 44, co-authored 139 publications receiving 6497 citations. Previous affiliations of Yoshimichi Okayama include Southampton General Hospital & National Institutes of Health.

Papers
More filters
Journal ArticleDOI

Interleukin 4 is localized to and released by human mast cells

TL;DR: It is proposed that mast cell activation in an allergic response provides a rapid and local pulse of IL-4 into the local environment essential for the triggering of T lymphocytes into sustainedIL-4 production and to initiate inflammatory cell accumulation and activation.
Journal ArticleDOI

Development, migration, and survival of mast cells.

TL;DR: The factors that regulate mast cell development, migration, and survival are discussed including cytokines that are secreted from activated T cells and other immune cells including mast cells themselves.
Journal ArticleDOI

IL-33 can promote survival, adhesion and cytokine production in human mast cells.

TL;DR: The hypothesis that IL-33 may enhance mast cell function in allergic disorders and other settings, either in the presence or absence of co-stimulation of mast cells via IgE/antigen–FcɛRI signals is supported.
Journal Article

Heterogeneity of human mast cells based on cytokine content.

TL;DR: The results indicate that in addition to exhibiting heterogeneity with respect to neutral protease content of the secretory granules, human mast cells are also heterogeneous withrespect to cytokine content.
Journal ArticleDOI

IL-33 induces IL-13 production by mouse mast cells independently of IgE-FcεRI signals

TL;DR: It is found that IL‐33, but not IL‐1β or IL‐18, induced IL‐13 and IL‐6 production by mouse bone marrow‐derived, cultured mast cells (BMCMCs) independently of IgE, and potential roles for IL‐ 33 in mast cell‐ and Th2 cytokine‐associated immune responses and disorders are suggested.